JP2019519467A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519467A5
JP2019519467A5 JP2018549808A JP2018549808A JP2019519467A5 JP 2019519467 A5 JP2019519467 A5 JP 2019519467A5 JP 2018549808 A JP2018549808 A JP 2018549808A JP 2018549808 A JP2018549808 A JP 2018549808A JP 2019519467 A5 JP2019519467 A5 JP 2019519467A5
Authority
JP
Japan
Prior art keywords
group
compound
cells
tumor
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018549808A
Other languages
English (en)
Japanese (ja)
Other versions
JP7073270B2 (ja
JP2019519467A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/023508 external-priority patent/WO2017165473A1/en
Publication of JP2019519467A publication Critical patent/JP2019519467A/ja
Publication of JP2019519467A5 publication Critical patent/JP2019519467A5/ja
Priority to JP2022077992A priority Critical patent/JP2022116028A/ja
Application granted granted Critical
Publication of JP7073270B2 publication Critical patent/JP7073270B2/ja
Priority to JP2024002743A priority patent/JP2024050608A/ja
Priority to JP2025172559A priority patent/JP2026021351A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018549808A 2016-03-22 2017-03-22 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 Active JP7073270B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022077992A JP2022116028A (ja) 2016-03-22 2022-05-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2024002743A JP2024050608A (ja) 2016-03-22 2024-01-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2025172559A JP2026021351A (ja) 2016-03-22 2025-10-14 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311697P 2016-03-22 2016-03-22
US62/311,697 2016-03-22
PCT/US2017/023508 WO2017165473A1 (en) 2016-03-22 2017-03-22 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022077992A Division JP2022116028A (ja) 2016-03-22 2022-05-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤

Publications (3)

Publication Number Publication Date
JP2019519467A JP2019519467A (ja) 2019-07-11
JP2019519467A5 true JP2019519467A5 (https=) 2020-04-30
JP7073270B2 JP7073270B2 (ja) 2022-05-23

Family

ID=59899817

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018549808A Active JP7073270B2 (ja) 2016-03-22 2017-03-22 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2022077992A Pending JP2022116028A (ja) 2016-03-22 2022-05-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2024002743A Pending JP2024050608A (ja) 2016-03-22 2024-01-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2025172559A Pending JP2026021351A (ja) 2016-03-22 2025-10-14 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022077992A Pending JP2022116028A (ja) 2016-03-22 2022-05-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2024002743A Pending JP2024050608A (ja) 2016-03-22 2024-01-11 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP2025172559A Pending JP2026021351A (ja) 2016-03-22 2025-10-14 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤

Country Status (27)

Country Link
US (3) US11458213B2 (https=)
EP (3) EP4385981A1 (https=)
JP (4) JP7073270B2 (https=)
KR (4) KR20220063298A (https=)
CN (3) CN120172884A (https=)
AU (1) AU2017238181B2 (https=)
BR (1) BR112018069507A2 (https=)
CA (1) CA3018709A1 (https=)
CL (1) CL2018002683A1 (https=)
CY (1) CY1124487T1 (https=)
DK (2) DK3925952T3 (https=)
ES (2) ES2972148T3 (https=)
FI (1) FI3925952T3 (https=)
HR (2) HRP20240215T1 (https=)
HU (2) HUE065327T2 (https=)
LT (2) LT3925952T (https=)
MX (1) MX384823B (https=)
PH (1) PH12018502048A1 (https=)
PL (2) PL3925952T3 (https=)
PT (2) PT3433238T (https=)
RS (2) RS62274B1 (https=)
RU (2) RU2021115958A (https=)
SA (1) SA518400103B1 (https=)
SI (2) SI3925952T1 (https=)
TR (1) TR201813644T1 (https=)
WO (1) WO2017165473A1 (https=)
ZA (1) ZA201806389B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019002560B1 (pt) 2016-08-10 2022-08-16 Cancer Targeted Technology Llc Composto, composição farmacêutica, seus usos e método de preparação do mesmo
EP3544960A1 (en) * 2016-11-23 2019-10-02 Cancer Targeted Technology LLC Albumin-binding psma inhibitors
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2018222778A1 (en) * 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
EP3494998A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Glycosylated psma inhibitors for imaging and endoradiotherapy
BR112020011727A2 (pt) * 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
EP3494999A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Psma ligands for imaging and endoradiotherapy
SG11202005511VA (en) * 2017-12-13 2020-07-29 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
SG11202007180QA (en) * 2018-02-06 2020-08-28 Univ Heidelberg Fap inhibitor
KR20250126870A (ko) * 2018-02-06 2025-08-25 더 존스 홉킨스 유니버시티 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트
JP7094591B2 (ja) * 2018-03-30 2022-07-04 フューチャーケム カンパニー リミテッド 前立腺がんを診断および処置するためのｐｓｍａ標的放射性医薬品
ES3034597T3 (en) * 2018-04-27 2025-08-20 Univ Iowa Res Found Compositions for chelating metals at low temperatures
WO2020065045A1 (en) * 2018-09-28 2020-04-02 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
KR102403970B1 (ko) * 2018-12-27 2022-05-31 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
CN120441497A (zh) * 2019-07-02 2025-08-08 先进加速器应用意大利公司 前列腺特异性膜抗原（psma）配体及其用途
WO2021001362A1 (en) 2019-07-02 2021-01-07 Advanced Accelerator Applications (Italy) Srl Prostate specific membrane antigen (psma) ligands and uses thereof
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
RU2730507C1 (ru) * 2019-08-27 2020-08-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе
CA3176404A1 (en) * 2020-04-24 2021-10-28 Ebrahim S. Delpassand Composition, kit and method for diagnosis and treatment of prostate cancer
US20230330278A1 (en) * 2020-04-29 2023-10-19 Novartis Ag Methods for radiolabelling psma binding ligands and their kits
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
JP2023550411A (ja) * 2020-11-19 2023-12-01 ノバルティス アーゲー 前立腺特異的膜抗原（ｐｓｍａ）リガンドの合成
MX2021005089A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos.
KR20240022616A (ko) * 2021-06-17 2024-02-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료
KR20230050552A (ko) * 2021-10-07 2023-04-17 (주)퓨쳐켐 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
CN120826245A (zh) * 2022-12-21 2025-10-21 梅约医学教育与研究基金会 将生物制剂与多种螯合剂组合的方法和材料
KR20260040237A (ko) 2023-07-21 2026-03-24 노파르티스 아게 Psma 표적 방사성 리간드 치료 요법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926573C (en) * 2007-06-26 2018-08-28 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
TW201034691A (en) * 2008-12-05 2010-10-01 Molecular Insight Pharm Inc Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof
EP3222617B1 (en) 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
CN113149921B (zh) * 2011-11-30 2024-11-29 约翰霍普金斯大学 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
EP3300746B1 (en) * 2013-01-14 2019-05-15 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
AU2015256002B2 (en) * 2014-05-06 2020-01-02 Northwestern University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
EP3183236B1 (en) 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
US11420910B2 (en) * 2014-10-30 2022-08-23 Katholieke Universitet Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US11520472B2 (en) * 2015-09-24 2022-12-06 Mitutoyo Corporation Inspection program editing environment including integrated alignment program planning and editing features
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy

Similar Documents

Publication Publication Date Title
JP2019519467A5 (https=)
RU2021115958A (ru) Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы
JP2015531371A5 (https=)
JP2010531304A5 (https=)
JP2020510054A5 (https=)
FI3917626T3 (fi) Psma:ta sitova kaksimuotoinen radiomerkkiaine ja terapeuttinen aine
JP2019513734A5 (https=)
JP2017537080A5 (https=)
JP2017538677A5 (https=)
RU2018100142A (ru) Гетероциклические соединения, эффективные для ингибирования киназы
JP2008535902A5 (https=)
JP2020525429A5 (https=)
JP2011515397A5 (https=)
RU2012141590A (ru) Соединения для лечения рака
JP2016503414A5 (https=)
JP2018525358A5 (https=)
JP2016519062A5 (https=)
RU2020102453A (ru) Фармацевтические композиции
JP2019529518A5 (https=)
JP2017536344A5 (https=)
JP2018507197A5 (https=)
JP2011522889A5 (https=)
JP2015512943A5 (https=)
JP2007515413A5 (https=)
JP2009515890A5 (https=)